A Scientific Statement From the AHA on CV Risk in Nonalcoholic Fatty Liver Disease
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
A team of investigators sought to identify the effect of glycemic control on risk for stroke among patients with atrial fibrillation.
Researchers report findings from the ACCORD trial that evaluated the relationship of a blood pressure polygenic risk score with cardiovascular outcomes in individuals with type 2 diabetes.
The American Society for Preventive Cardiology issued a clinical practice statement regarding risk assessment for atherosclerotic cardiovascular disease.
Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
Investigators assessed the impact of treatment with empagliflozin on patients with type 2 diabetes and chronic obstructive pulmonary disease.
A study was conducted to determine the relationship between breast arterial calcification and risk for atherosclerotic cardiovascular disease.
Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.
Study finds cardiovascular risk factors to be associated with an increased risk for depression in older adults.
Beta-blocker pharmacokinetics comparison chart for hypertension.